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Purpose: The main goal of this study is to evaluate the impact of physical incorporation of
polyethylene glycol (PEG) into 5-fluorouracil (5-FU)-loaded polymeric nanoparticles (NPs).
Methods: The 5-FU-loaded NPs were prepared utilizing a simple double emulsion method
using polycaprolactone (PCL) and polylactic-co-glycolic acid (PLGA) with or without PEG
6000. The surface charge, particle size, and shape of NPs were evaluated by standard
procedures. Both Fourier Transform Infrared Spectroscopy and X-ray diffraction spectra of
the 5-FU loaded NPs were compared against the pure 5-FU. The in vitro release profile of
5-FU from the NPs was monitored by the dialysis tubing method. Cell death and apoptosis
induction in response to 5-FU NP exposure were measured by MTT and Annexin–V/7-
amino-actinomycin D (7-AAD) assays, respectively, in Daoy, HepG2, and HT-29 cancer cell
lines.
Results: The 5-FU loaded NPs were found to be spherical in shape with size ranging
between 176±6.7 and 253.9±8.6 nm. The zeta potential varied between −7.13± 0.13 and
−27.06±3.18 mV, and the entrapment efficiency was between 31.96% and 74.09%. The in
vitro release of the drug followed a two-phase mode characterized by rapid release in the first
8 hrs followed by a period of slow release up to 72 hrs with composition-based variable
extents. Cells exposed to NPs demonstrated a significant cell death which correlated with the
ratio of PEG in the formulations in Daoy and HepG2 cells but not in HT-29 cells.
Formulations (F1–F3) significantly induced early apoptosis in HT-29 cell lines.
Conclusion: The physical PEGylation significantly enhanced the entrapment and loading
efficiencies of 5-FU into NPs formulated with PLGA and PCL. It also fostered the in vitro
cytotoxicity of 5-FU-loaded NPs in both Daoy and HepG2 cells. Induction of early apoptosis
was confirmed for some of the formulations.
Keywords: hepatocellular carcinoma HepG2, emulsification-solvent evaporation technique,
colorectal carcinoma HT-29, MTT assay, apoptosis
Introduction
Cancer nanomedicine is considered a relatively recent interdisciplinary research area
cutting across chemistry, engineering, pharmaceutical drug delivery, and medicine with
the goal to drive major enhancement in both diagnosis and treatment of cancer.1,2 During
the last decade, many research articles were published presenting smart targeted nano-
drug delivery particulate systems for specific ways of enhanced tumor therapy and
imaging where many reviews have tried to define and classify those NPs systems.3,4
They all agreed to describe such systems as nano-sized composites able to incorporate
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drug(s) and/or contrast agent(s) and they can be either nano-
carriers or nanovectors.5 They were particularly composed of
a scaffold mainly made from a corona of polymers able to
enhance many biopharmaceutical and pharmacokinetic prop-
erties of incorporated drugs or contrast agents. They can also
have a ligand attached to their surfaces that provides targeting
for a specific cancer biomarker overexpressed in certain cancer
cells.6
Nanoparticulate drug delivery is an evolving research
field aiming to apply the beneficial attributes of nanotech-
nology in developing new advantageous therapeutic sys-
tems including polymeric biodegradable nanoparticles,7
ceramic nanoparticles,8 polymeric micelles,9 liposomes,10
dendrimers,11 and solid lipid nanoparticles.12
Nanoparticulate systems made of biodegradable poly-
mers are considered effective controlled release drug
delivery systems in which a drug is entrapped, encapsu-
lated, or adsorbed. Lactic acid and glycolic acid-based
polymers, and their hybrid co-polymer PLGA are consid-
ered the most commonly used biodegradable polymers due
to their biocompatible, nontoxic properties and their ability
to prolong drug residence time at the target sites.13
The 5-FU is a pyrimidine analogue antimetabolite,
which is used in the treatment of many types of cancer
including anal, colorectal, stomach, pancreatic, breast, and
head and neck cancers.14 It was listed by World Health
Organization (WHO) among the most important drugs
needed in a basic health system.15 The 5-FU is considered
a narrow therapeutic index drug with very close minimum
effective dose and maximum tolerated dose, in addition to
its high inter-subject pharmacokinetic variability.16,17
Because of the high metabolism rate, the drug elimination
half-life is usually less than 20 mins, and this requires a
continuous administration of large doses and consequently
resulting in multiple adverse effects such as severe nausea
and vomiting, diarrhea, and severe anemia.18–20 The antic-
ancer effects of 5-FU are highly dependent on the duration
of tumor exposure to the drug and not on the blood levels
of the drug.21 The incorporation of 5-FU in a nanoparti-
culate drug delivery would have a positive impact on the
anticancer therapeutic efficacy through prolonging the
drug retention time inside the body and thereby reducing
the dose and all dose-related adverse effects. In addition to
the high tendency of nanoparticles to accumulate in tumors
as a result of the enhanced permeation and retention (EPR)
effect, a tumor characteristic that has been exploited by
Matsumura and Maeda22 as a mean to target anticancer
agents to solid tumors.
In the present study, we investigated the impact of
physical PEGylation of biodegradable polymeric nanopar-
ticles on the anticancer activity of 5-FU NPs in medullo-
blastoma (Daoy), hepatocellular carcinoma (HepG2), and
colorectal carcinoma (HT-29) cell lines.
Materials And Methods
Materials
Poly(D,L-lactide-coglycolide) (50:50) (Mw: 12,000 g/mol
(PLGA), Polycaprolactone (PCL; Mw: 42,000 Da), MTT
(3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium
bromide), Poly (ethylene glycol) PEG Mn average 6000,
and 5-FU were purchased from Sigma-Aldrich Chemical
Co. (St Louis, MO). Polyvinyl alcohol (PVA) with a
molecular weight of 16,000 and dichloromethane (DCM)
were obtained from Acros Organics (Geel, Belgium).
DMEM and DMEM/F12, FBS, L-glutamine, and
penicillin/streptomycin were obtained from Gibco Inc.
(NY, USA). Annexin V-Phycoerythrin (PE) kit/7-amino-
actinomycin D (7-AAD) was obtained from Invitrogen
(CA, USA). All other reagents and chemicals were of
analytical grade.
Preparation Of 5-FU-Loaded
Nanoparticles
The 5-FU NPs were prepared with 6 different formulation
compositions described as F1, F2, F3, F4, F5, and F6 to
optimize high drug entrapment efficiency and low particle
size, and to evaluate the impact of physical incorporation
of PEG. Table 1 shows the composition of each of the six
formulations.
The double emulsion-solvent evaporation method was
employed for loading 5-FU into polymeric NPs a reported
previously.23
Briefly, an aqueous solution of 5-FU (4mg/mL) was
prepared in purified water by vortex mixing. The organic
Table 1 The Composition Of 5-Fluorouracil (5-FU)-Loaded
Nanoparticles
Codes 5-FU (mg) PLGA (mg) PCL (mg) PEG 6000 (mg)
F1 4 20 – –
F2 4 – 20 –
F3 4 – 20 4
F4 4 – 80 60
F5 4 40 – 10
F6 4 80 – 60
Abbreviations: 5-FU, 5-fluorouracil; PLGA, Poly lactide-co-glycolide; PCL, Poly-
caprolactone; PEG 6000, Poly ethylene glycol 6000.
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phase was prepared by dissolving the required weights of
polymer(s) in 10 mL of DCM. One mL of 5-FU solution
was emulsified in 10 mL of DCM using a probe-sonicator
for 1 min at 40% power under ice bath. The secondary
emulsion was formed by emulsifying the primary emul-
sion into 40 mL of an aqueous solution of 1% PVA using
another 3-min probe-sonication period. The mixture was
stirred at room temperature (22°C) and at 500 rpm under
hood for at least 3 hrs to remove the DCM. The NPs
dispersion was subjected to three cycles of centrifugation
at 10,000 rpm for 10 mins followed by decantation of the
supernatant solution and re-dispersion in double-distilled
water. The supernatant solutions were analyzed for drug
contents by HPLC analysis and used to calculate % entrap-
ment efficiency (EE%). The residue was dispersed in 1.2%
sodium lauryl sulfate solution by vortexing for 5 mins and
lyophilized using a freeze dryer (Alpha 1–4 LD Plus,
Martin Christefriertrocknugsanlagen GmbH, Osterode am
Harz, Germany) at −60°C for 3 days. All formulations
were prepared in triplicate.
Particle Size And Zeta Potential
A Zetasizer Nano ZS (Malvern Instruments, UK) was
utilized for monitoring the mean particle size and poly-
dispersity index (PDI) of each formulation at the 25°C
after proper dilution. The same instrument was also used
for measuring the zeta potential by applying the Laser
Doppler Velocimetry (LDV) mode at 25°C. All experi-
ments were performed in triplicate. Each value reported
is the average of five measurements.
Entrapment Efficiency And Drug Loading
The efficiency of 5-FU entrapment into NP formulations was
indirectly obtained by determining the concentration of 5-FU
in the supernatant obtained after subjecting them to ultracen-
trifugation for 30 mins at 40,000 rpm in OptimaTM Max-E,
Ultra Centrifuge (Beckman Coulter, Pasadena, CA) at 4°C.
The amount of non-entrapped 5-FU in the supernatant was
determined by an HPLC method.
The following Equations 1 and 2 were used to calculate
both entrapment efficiency (EE%) and drug loading (DL%)
respectively:
EE% ¼ 5 FUtotal5 FUfree
5FUtotal
100 (1)
DL% ¼Amount of entrapped 5 FU
Total weight
100 (2)
The Particle Morphology
The particle shape and surface topography of the 5-FU-
loaded NP formulations were examined by scanning electron
microscopy (JSM-6360 LV, JEOL, Tokyo, Japan). The dried
samples were first fixed on carbon tape and then subjected to
gold coating under argon atmosphere applying a gold sputter
module in a high-vacuum evaporator (JFC-1100 fine coat ion
sputter; JEOL). The gold-coated samples were then exam-
ined at different magnification levels. Photomicrographs
were taken at an acceleration voltage of 10 kV.
X-Ray Diffraction
Powder X-ray diffraction (PXRD) was utilized to monitor
any changes in the crystalline nature of 5-FU-loaded NP in
comparison to pure powder. Wide-angle X-ray diffract-
ometer (Rigaku Ultima IV, Tokyo, Japan) was employed
to monitor PXRD patterns using CuKα radiation. A 2
range of 5–60° was set for sample scanning.
Fourier Transform Infrared Spectroscopy
(FTIR)
FTIR (Thermo Scientific, Nicolet 380, USA) was employed
for monitoring any changes in the FTIR spectra of NPs
loaded 5-FU from the pure powder using the potassium
bromide (KBr) disc technique. Simply, a small portion of
each sample was mixed with KBr and discs were obtained
by compression using a hydraulic press. Scanning of discs
was done from 5000 to 400 cm−1 using transmission model.
In Vitro Release Study
Dialysis membrane bag method was employed to monitor
in vitro release profile of 5-FU from NP formulations.
Phosphate-buffered saline (PBS, pH 7.4) was used as the
receptor compartment. Briefly, freeze-dried NPs equiva-
lent to 5 mg of the 5-FU were dispersed in 1 mL distilled
water and instilled into the dialysis bag (molecular weight
cut off: 5 kDa, Livingstone, NSW, Australia) which were
placed in a beaker containing 40 mL of preheated PBS, pH
7.4. The beakers were kept in a thermostatic shaker water
bath at 37°C and 100 rpm. Five mg of pure 5-FU pro-
cessed similarly was used as a control. Three beakers were
used for each formulation. At certain time intervals, 3 mL
samples were withdrawn from each beaker and replaced
by the same volume of fresh media pre-heated at 37°C to
maintain sink condition. The amount of 5-FU in each
sample was determined using an HPLC method.
Dovepress Ashour et al
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HPLC Analysis
A reverse-HPLC method reported earlier by Alanzi et al24
was used for the analysis of 5-FU in each sample. The
HPLC system (WatersTM 600 controller Milford, MA,
USA) containing a dual λ UV detector (WatersTM 2487
detector Milford, MA, USA). The system contains a bin-
ary pump (WatersTM 1252 pump Milford, MA, USA) and
an automating sampling system (WatersTM 717 Plus
Milford, MA Autosampler, USA). A mobile phase com-
posed of 40 mM phosphate buffer adjusted to pH 7.0 by
10% w/v potassium hydroxide was used and samples were
pumped through C18 column (BondapakTM, 4.6 ×
150 mm, 10 m particle size) at a rate of 1 mL/min. The
injection volume was 20 μL and the UV detector was
adjusted at λ=260 nm. All the operations were carried
out at ambient temperature.
Cell Lines, Cell Culture, And Chemicals
Three cancer cell lines were utilized in this study,
namely the hepatocellular carcinoma HepG2, the
human colorectal cancer HT-29, and medulloblastoma
Daoy cells. These cell lines were obtained from
American Type Culture Collection (ATCC, Manassas,
VA, USA). HepG2 and HT-29 cells were aseptically
cultured in DMEM/high glucose supplemented with
10% heat-inactivated fetal bovine serum (FBS),
2 mM L-glutamine, and 1% penicillin–streptomycin.
Daoy cells were aseptically grown in DMEM/F12 med-
ium, supplemented with 1% non-essential amino acids,
0.04% HEPES, in addition to the above-mentioned
additives. All cells were maintained in a humidified
atmosphere of 5% C02 at 37°C. Cells were kept in
the logarithmic growth phase by routine passage
every 3–4 days utilizing 0.025% trypsin-EDTA treat-
ment. 5-FU was purchased from Sigma-Aldrich
Chemical Co. (St. Louis, MO, USA). 5-FU and 5FU-
loaded NPs were dispersed in phosphate-buffered sal-
ine (PBS, pH 7.4) and used in the in vitro cytotoxicity
and apoptosis studies at 5-FU concentration of
2.5 µg/mL which is equal to 19.22 µM. NP dispersions
were prepared by weighing the equivalent weights from
the freeze-dried powders under aseptic condition and
dispersed in the required volume of PBS previously
syringe-filtered using 0.45 µm membrane filters to
ensure sterility. The dispersion was further sonicated
for 30 mins using a bath sonicator.
In Vitro Cytotoxicity Studies
The cytotoxicity of 5-FU-loaded NPs was assessed by MTT
assay in Daoy, HepG2, and HT-29 cells.25 Cells were grown
in Dulbecco’s Modified Eagle’s Medium (DMEM) and
DMEM/F12 at a density of 1–2 × 104 cells per well in 96-
well plates in a humidified atmosphere of 5% CO2 at 37°C
for 24 hrs. Following this, culture media were replaced with
fresh DMEM media containing 5% FBS and cells were
exposed to different 5-FU NP formulations containing
5-FU (2.5 μg/mL which is equivalent to 19.22 μM), pure
5-FU (2.5 μg/mL) or unloaded NPs for 24, 48, or 72 hrs. The
culture media were replaced with 100 μL/well of MTT solu-
tion [0.5 mg/mL in phosphate-buffered saline (PBS)] and
cells were further incubated for 3 hrs. Following this, MTT
solution was removed and 100 μL of isopropyl alcohol was
added to each well and the plates were left on a shaker for 2
hr at room temperature. The absorbance wasmeasured at 549
nm in an ELISA reader (ELX 800; Bio-Tek Instruments,
Winooski, VT, USA). The resulting absorbance was com-
pared with the mean absorbance of the control wells contain-
ing only buffer in order to determine the cell viability. The
following equation was used to calculate the cell viability.26
% cell viability¼ A549 nmof treated cells=
A549 nmof control cells
 
 100 (3)
Detection Of Apoptosis By Flow
Cytometry
Annexin-V-PE/7-AAD assay was employed to monitor the
early apoptosis induced by 5-FU-loaded NPs as described
earlier.27,28 Briefly, cells were grown as described above.
Culture media were removed from the wells and cells were
washed once with PBS, binding buffer (500 μL/well)
(Invitrogen, CA, USA) and Annexin-V-PE (7 μL/well)
(Invitrogen, CA, USA) were added to each well and the
plate was incubated at room temperature for 10 mins.
After this, 7 μL of 7-AAD was added to each well, and
plates were further incubated at room temperature for
another 10 mins. Excess label was washed with binding
buffer and cells were harvested by scraping in binding
buffer (700 μL/well). Cells were immediately analyzed
by flow cytometry on Cytomics FC 500 (Beckman
Coulter, Fullerton, CA, USA), and CXP acquisition and
analysis software was used for data processing. The fluor-
escence of Annexin V-PE was analyzed on FL2 (575 nm)
after exciting cells with a 488 nm argon laser line whereas
Ashour et al Dovepress
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fluorescence of 7-AAD was analyzed on FL4 (608 nm), as
reported by Merkel et al (2008).29
Statistical Data Analysis
The software package Microsoft Excel, Version 2010,
Origin software, version 6.1 and GraphPad InStat version
3 was used for data analysis. Results are expressed as
mean ± standard error (n = 3–8 independent samples).
Results
Particle Size And Zeta Potential
Measurements
Six different formulations of 5-FU-loaded NPs were prepared
to evaluate the effect of physical PEGylation using two differ-
ent polymers; PLGA and PCL. The exact composition of each
formulation is shown in (Table 1). Particle size, PDI, and zeta
potential of NPs for each of the prepared formulations are
shown in Table 2. It was observed that all prepared NP
formulations exhibited very close low particle sizes between
176.3±6.7 nm for F3 to 253.9±8.6 nm for F4. They also
exhibited a narrow range of particle size distribution indicated
by low PDI (<0.25) except for F4 (0.317). These results
indicate that the method of preparation was well optimized
to produce 5-FU loaded NPs of small uniform sizes.
The zeta potential values were −17.47±1.88, −9.22
±0.47, −8.52±1.22, −27.06±3.18, −7.13±0.13, and −13
±0.41 for F1, F2, F3, F4, F5, and F6, respectively. Such
negative surface charge of all NP formulations is attributed
to the existence of numerous free carboxylic acid groups
within the chemical structure of the PLGA and PCL poly-
mers present on NP surfaces.
Yield, Entrapment Efficiency, Drug
Loading, And Particle Morphology
Table 3 shows the effect of the polymer and copolymer
nature on the percent yield, entrapment efficiency (EE),
and drug loading (DL) of 5-FU into NPs. Generally, all
formulations showed relatively high percent yield values
indicating the robustness of preparation method. It is
clear that the incorporation of PEG 6000 in the compo-
sition of NPs significantly enhanced both percent EE
and DL. They were found to be dependent on the nature
of the polymer and the magnitude of PEG 6000. An
increase in EE% from 32 to 74 and DL% from 7 to 32
were recorded for F1and F5, respectively. These results
revealed that both F5 and F6 exhibited a significant
higher EE % and DL% than other NP formulations.
They are both composed of different ratios of PLGA
and PEG 6000. Increasing the polymers portion in the
ratio of drug: PCL: PEG6000 was found to significantly
enhance both the %EE and %DL as indicated from the
higher %EE (68.29%) and drug loading (21.27%)
achieved with F4 (1:20:15) compared with lower values
(44.24% for %EE and 12.72% for %DL) obtained with
F3 (1:5:1).
The SEM images depict almost spherical shape for all
of 5-FU-loaded NPs with smooth surfaces (Figure 1).
Some of the images showed aggregation of NPs which is
probably attributed to the high surface activity and condi-
tions of the drying process.
X-Ray Diffraction (XRD) And Fourier
Transform Infrared Spectroscopy (FTIR)
Figure 2 depicts the XRD spectra of the six 5-FU-loaded
NP formulations in comparison to pure 5-FU powder. The
spectrum of pure 5-FU shows a peak near 30° at the 2Ө,
which can be ascribed to its crystalline nature. The appear-
ance of the broad peaks in 2Ө = 10°–25° is due to the
amorphous nature of PLGA polymer. But in the presence
of PCL polymer, crystalline peaks at 21.1° and 24.0° were
observed (Figure 2). The XRD of 5-FU-loaded NP formu-
lation indicates the disappearance of the characteristic
peak for 5-FU.
Table 2 The Physicochemical Characterization Of 5-FU-Loaded
Nanoparticles
Codes Particle Size
(nm)
PDI Zeta Potential
(mV)
F1 241.1±9.8 0.137±0.032 −17.47±1.88
F2 193.5±6.3 0.151±0.081 −9.22±0.47
F3 176.3±6.7 0.274±0.037 −8.52±1.22
F4 253.9±8.6 0.317±0.081 −27.06±3.18
F5 221.3±7.9 0.243±0.068 −7.13±0.13
F6 204.3±6.4 0.211±0.065 −13.74±0.41
Table 3 The Yield %, Entrapment Efficiency (EE %) And Drug
Loading (DL%) Of 5-FU-Loaded Nanoparticles (Mean ± S. D., N = 3)
Codes Yield % EE% DL%
F1 72.36±3.41 31.96±1.04 7.15±1.05
F2 61.23±2.55 37.89±0.85 8.61±0.24
F3 82.87±1.22 44.24±1.32 12.72±1.59
F4 85.29±3.44 68.29±2.64 21.2.7±2.98
F5 87.11±1.87 74.09±2.13 30.65±4.41
F6 80.82±4.23 73.54±1.62 24.33±3.88
Dovepress Ashour et al
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Figure 3 shows FTIR spectra of the six 5-FU-loaded NP
formulations compared with pure 5-FU. The characteristic
bands of pure 5-FU are detected at 1722, 1430, 1246, 811,
and 551 cm−1 resulting from the vibration of imide stretch
(amide II and amide III) and aromatic ring, 1348 cm−1
associated with the vibration of the pyrimidine ring,
1181 cm−1 assigned to the C=O vibrations, and 1246 cm−1
associated with C-N vibrations. While the spectra of NP
formulations have shown the amide group bands in the
range between 1470 and 1760 cm−1 and the carbonyl band
Figure 1 SEM micrographs of 5-FU loaded nanoparticles.
Notes: F1 (composed of 1:5:0, drug:PLGA:PEG6000), F2 (composed of 1:5:0, drug:PCL:PEG6000), F3 (composed of 1:5:1, drug:PCL:PEG6000), F4 (composed of 1:20:15,
drug:PCL:PEG6000), F5 (composed of 1:5:1, drug:PLGA:PEG6000), and F6 (composed of 1:20:15, drug:PLGA:PEG6000).
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observed at 1733 cm−1. It also depicts -CH2 stretching
bands in the range of 2851–2920 cm−1 and C=O stretching
in the range of 1081–1252 cm−1. The C-H stretching band
was demonstrated as a characteristic peak in the range of
3136–2830 cm−1. Generally, the spectrum of NP formula-
tions kept the sharpest characteristic peaks of 5-FU with
slight shifting.
In Vitro Release Studies
Figure 4 illustrates the 5-FU release profiles from the six NP
formulations in comparison to 5-FU dispersion in distilled
water as a reference. The release profile of the reference
indicated instant release for most of the drug within the first
hour. On the other hand, a bi-phasic pattern has been followed
with all NP formulations characterized by an 8 h first rapid
release phase followed by a second phase of slow-release
extending until 72 hrs. The extent of this pattern was variable
depending on the polymeric composition of each formulation.
The cumulative% released values of 5-FU from the NPs in the
first 8 hrswere about 39%, 26%, 53%, 59%, 60%, and 63% for
F1, F2, F3, F4, F5, and F6, respectively, while they achieved a
maximumof about 47%, 36%, 66%, 70%, 75%, and 84% after
72 hrs. The slow release could be caused by the diffusion of
the drug from the NPsmatrix following the slow erosion of the
polymer.
The kinetics of the release data was analyzed using the
DDSolver software program. The fitting of the data was
assessed in multiple kinetic models including zero, first,
Higuchi and Korsmeyer-Peppas. Table 4 presents the square
of the regression values (R2) and the Korsmeyer-Peppas
exponent (n) for all of the 6 formulations (F1–F6). The
results indicated the high compliance of the 5-FU release
from the six NP formulations with Korsmeyer-Peppas as
shown from the significant higher R2 values. Moreover, the
values of n are in the range from 0.157 to 0.282, thus far
below 0.5 pointing out a Fickian diffusion kinetics.
In Vitro Cytotoxicity
We assessed the cytotoxicity of all 5-FU-loaded NP
formulations -(F1–F6) and their corresponding controls
including drug-free NP formulations and pure 5-FU in
HT-29, HepG2, and Daoy cancer cells by MTT assay.
We used 5-FU in a concentration of 2.5 μg/mL, which is
equal to 19.22 μM. This concentration is equivalent to
the IC50 of 5-FU on HT-29 cells reported by Nita et al
30
who concluded that the IC50 of 5-FU in HT-29 was 19.3
μM after 72 hrs of incubation. It is generally noticed
that the cytotoxic activity of both 5-FU-loaded NPs and
pure 5-FU is highly time-dependent. It is obvious from
Figures 5–7 that loading of 5-FU into such NP formula-
tions significantly fostered the cytotoxicity of 5-FU, as
compared to pure 5-FU in the three tested cell lines, but
with different potencies at different time points. This is
an interesting finding, considering the incomplete and
slow in vitro release of 5-FU from NPs in the 72-hr
period, in contrast with the instant solubility of pure 5-
FU in the cell culture medium. The results also demon-
strated that significant anticancer activity was achieved
for all 5-FU-loaded NP formulations as well as pure 5-
FU in all the three tested cancer cell lines, as compared
to the buffer (control), but with different potencies at
different time points. As shown in Figure 6, the F1, F4,
F5, and F6 formulations significantly enhanced the cyto-
toxicity of 5-FU, relative to pure 5-FU in HepG2 cells
after 24 hrs of incubation. The F5 formulation signifi-
cantly increased the antiproliferative activity of 5-FU,
relative to pure 5-FU in HepG2 cells after 48 hrs of
incubation. All 5-FU-loaded NPs, except F4, signifi-
cantly enhanced the cytotoxicity of 5-FU, relative to
Figure 2 XRD diffractograms of pure 5-FU and 5-FU-loaded nanoparticles.
Notes: F1 (composed of 1:5:0, drug:PLGA:PEG6000), F2 (composed of 1:5:0, drug:
PCL:PEG6000), F3 (composed of 1:5:1, drug:PCL:PEG6000), and F5 (composed of
1:5:1, drug:PLGA:PEG6000).
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Figure 3 FTIR spectra of pure 5-FU and 5-FU-loaded nanoparticles.
Notes: F1 (composed of 1:5:0, drug:PLGA:PEG6000), F2 (composed of 1:5:0, drug:PCL:PEG6000), F3 (composed of 1:5:1, drug:PCL:PEG6000), and F5 (composed of 1:5:1,
drug:PLGA:PEG6000).
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pure 5-FU in HepG2 cells after 72 hrs of incubation. F5
(PLGA-PEG) was the most potent formula among all 5-
FU-loaded NPs against HepG2 cells at all durations.
The F5 formulation induced 70%, 60%, and 72% cell
death after 24, 48, and 72 hrs, respectively. With regard
to Daoy cells, F1, F3, and F5 significantly improved the
cytotoxicity of 5-FU, relative to pure 5-FU after 24 hrs
of incubation (Figure 5). All 5-FU-loaded NPs, except
F4, significantly augmented the cytotoxicity of 5-FU,
relative to pure 5-FU in Daoy after 48 hrs of incubation.
The formulations F4, F5, and F6 significantly amelio-
rated the cytotoxicity of 5-FU, relative to pure 5-FU in
Daoy after 72 hrs of incubation. Interestingly, F5 was
also the most potent formulation among all 5-FU-loaded
NPs against Daoy cells at all durations. It induced 34%,
61%, and 74% cell death after 24, 48, and 72 hrs,
respectively. The formulations F1, F2, and F3 signifi-
cantly enhanced the cytotoxicity of 5-FU, relative to
pure 5-FU against HT-29 after 72 hrs incubation as
depicted in Figure 7. These formulations induced 60%
cell death after 72 hrs, whereas pure 5-FU inhibited HT-
29 cell proliferation by about 51%; similar to results
reported by Nita et al30 who showed that 5-FU induced
50% cell death of after 72 hrs.
Induction Of Apoptosis In HT-29 Cells
Caused By 5-FU NPs
The most potent 5-FU NP formulations (F1–F3) which
showed the highest antiproliferative effects as shown in
Figure 7 were selected for measuring apoptosis. Unloaded
nanoparticles (F1–F3) and pure 5-FU were used as negative
and positive controls respectively. The results showed that
the three formulations significantly increased the percent of
Annexin V-PE positive/7-AAD negative (early apoptotic)
cells, compared to control as well as to 5-FU which induced
only modest pro-apoptotic effects as shown in Figure 8A
and B. These data indicated that 5-FU NP formulations 1, 2,
and 3 are capable of inhibiting HT-29 human colon cancer
cell growth, at least in part, by stimulating early apoptosis.
Discussion
The entrapment of 5-FU into polymeric NPs was intended to
prolong the residence time of the drug inside the body and
thereby to improve the cellular uptake of drugs by cancer cells.
The above strategy was aimed to significantly enhance the
antitumor activity and the overall therapeutic efficacy of 5-
FU. The use of PLGA and PCL-based NPs as targeted drug
delivery systems has been reported to be successful in different
cancer types.31,32 Among the used polymeric NPs, PCL NPs
have shown lower particle size than that of PLGA due to their
higher flexibility.33 Consistently, in the present study, the par-
ticle size of F2 (PCL-based formulation)was lower than that of
F1 (PLGA-based formulation). The existence of many free
carboxylic acid groups on the surface of both PLGA and
PCL indicates negative surface charge on all of the prepared
NP formulations. Moreover, it was observed that the incor-
poration of PEG in the NPS composition has resulted in a
reduction in the magnitude of zeta potential value as a result
of the PEG induced shielding effect on the NP surfaces.34 The
reproducible low particle sizes and PDI are indicative of high
Figure 4 Release profiles of 5-FU from loaded nanoparticles in phosphate buffer
pH 7.4 through dialysis bags with cut-off 12,000 Dalton using 5-FU aqueous solution
as a control (mean ± SD, n = 3).
Table 4 Release Kinetics Of 5-FU Release From Different NP Formulations
Codes Zero Order First Order Higuchi (Diffusion) Korsmeyer Peppas “n” value
F1 0.6609 0.7364 0.8921 0.9730 0.177
F2 0.7491 0.7934 0.9001 0.9602 0.282
F3 0.6607 0.9031 0.8326 0.9673 0.184
F4 0.6135 0.8879 0.7876 0.9600 0.157
F5 0.6710 0.9267 0.8372 0.9796 0.172
F6 0.7170 0.9479 0.8710 0.9800 0.199
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physical stability and reduced aggregation of NPs. The signifi-
cantly higher%EE observed with both F5 and F6 formulations
could be attributed to the presence of PEG 6000 together with
PLGA, which have the ability to create an irregular crystalline
network. This may promote more space for the drug
molecules.35 On the other hand, the lower %EE and %DL
obtained for F1 might be ascribed to higher precipitation of
polymers during NP preparation.35 Moreover, it is clear from
our results that PEGhas a valuable effect on the EE of the drug.
This actionmight be explained by the amphiphilic nature of the
polymer blends PEG/PLGA and PEG/PCL.36,37
Commonly higher particle sizes obtained by DLS in
contrast to those obtained by SEM might be related to the
tendency of NPs to swell in aqueous media.38 In addition,
DLS measures the diameter of stagnant solvent layer adja-
cent to the NPs, while the SEMmeasures the exact diameters
of NPs in the dry state.
The absence of the characteristic peaks of 5-FU from
the XRD spectra in NP formulations indicates the exis-
tence of the polymer matrix entrapped 5-FU in the amor-
phous state. The XRD analysis suggests that the majority
of 5-FU molecules were deeply incorporated within the
NPs matrix rather than adsorbed on their surfaces. This
was also confirmed by the FTIR by the slight shifting of
the characteristic peaks of 5-FU observed in NP formula-
tions and the appearance of C-H and C=O stretching
peaks. These findings indicated that slight chemical inter-
action between the drug and the polymer, which revealed
that the drug was encapsulated inside the polymer.
The slower release obtained with PCL-based NP formula-
tions can be attributed to the higher crystalline nature of PCL
than PLGA.39 In addition, PCL has much less water perme-
ability, which possibly led to very slow degradation rate.40
Therefore, the improved 5-FU release from PCL polymer
was dependent on the incorporated PEG 6000 in the case of
formulations F3 and F4. The increased release of 5-FU from
NPs in the presence of PEG 6000 might be attributed to a
higher degree of water permeability imparted by the surface
PEG.32,41
In addition, the higher release rate of 5-FU from PLGA
containing NPs (F1, F5, and F6) likely attributed to the
hydrophilic glycolide units resulting in improved water
Figure 5 Effect of several formulas of 5-FU-loaded nanoparticles on human medulloblastoma cells. Daoy cells were treated with indicated formulas of 5-FU-loaded
nanoparticles (5-FU-Fx), unloaded nanoparticles (U-Fx), pure 5-FU or buffer (control) for 24, 48, or 72 hrs. Cell viability was determined by MTT assay as indicated in
Methods. At the end of the assay, the absorbance at 549 nm was read on a microplate reader. Significant differences between treatments and control and 5-FU were analyzed
by ANOVA followed by unpaired t-test. *p < 0.05 compared with control (0 µM). #P<0.05 compared with 5-FU.
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permeability, thereby increasing drug release rate.42,43 The
significant increase in the 5-FU release rate observed in the
case of F5 and F6 compared to F1 can be explained by the
muchmore hydrophilicity andwater permeability induced by
the incorporation of PEG in the NP formulations. This was
also concluded by Sanna et al.35 The kinetic analysis of the
drug release profile from the NP formulations denoted a
Fickian diffusion model for all of the six formulations; there-
fore, a combination of diffusion and erosion which better
explains the bi-phasic release pattern with faster initial fol-
lowed by a much slower release rate. This is in agreement
with the interpretation introduced by a number of previous
reports.44,45
It is generally noticed that the cytotoxic activity of 5-FU-
loaded NPs and pure 5-FU was time-dependent. This corro-
borates previous findings where prolonged exposure of
colon, glioma, and breast cancer cells has been reported to
enhance 5-FU cytotoxicity.46,47 In the present study, the level
of cell death obtained with 5-FU NPs is much greater than
58% growth inhibition induced by 5-FU amphiphilic nano-
micelles in HepG2 cells48 and by porous 5-FU-loaded hydro-
gel microparticles which induced only 6%, 31% and 33%
HepG2 cell death after 24, 48, and 72 hrs, respectively.49
The significant enhancement of 5-FU cytotoxicity against
Daoy cells due to its incorporation into NPs confirms our
previous study showing increased cytotoxic effects of 5-FU
NPs in Daoy cells.50 To the best of our knowledge, this is the
first study to investigate the cytotoxicity of pure 5-FU and 5-
FU NPs using medulloblastoma cells. In the case of HT-29
cells, F5 was the only formulation that significantly increased
the cytotoxicity of 5-FU, relative to pure 5-FU after 24-hr
incubation. Even though the F1 and F3 formulations did not
significantly enhance 5-FU cytotoxicity against HT-29 after
48-hr incubation, both pure 5-FU as well as F1 and F3 caused
significant cytotoxicity with 37% cell death. This is much
higher, compared to 25% and 30% HT-29 cell death induced
by 5-FU-loaded liposome and 5-FU-loaded folate-liposomal
NPs with a 25 μM concentration of 5-FU as reported by
Handali et al.51 Importantly, the 25 μM concentration of 5-
FU used in their study was higher than 19.22 μM 5-FU used
Figure 6 Effect of several formulas of 5-FU-loaded nanoparticles on human hepatocellular carcinoma cells. HepG2 cells were treated with indicated formulas of 5-FU-loaded
nanoparticles (5-FU-Fx), unloaded nanoparticles (U-Fx), pure 5-FU or buffer (control) for 24, 48, or 72 hrs. Cell viability was determined by MTT assay as indicated in
Methods. At the end of the assay, the absorbance at 549 nm was read on a microplate reader. Significant differences between treatments and control as well as 5-FU were
analyzed by ANOVA followed by unpaired t-test. *p < 0.05 compared with control (0 µM). #P<0.05 compared with 5-FU.
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in the present study. Apparently our three formulations (F1-
F3) are much more potent in killing HT-29 cells than 5-FU-
PLGA NPs used in a previous study.46 Although they
achieved higher cell death (68%) as compared to 60% in
our study, they used 250 μM 5-FU which is a much higher
concentration than 19.22 μMused in this study. Interestingly,
our three formulations, F1, 2, and 3, showed a decent and
similar time-dependent cytotoxicity amounting to about
14%, 36%, and 60% after 24, 48, and 72 hrs incubation,
respectively, in HT-29 cells, further confirming the time-
dependent cytotoxicity of 5-FU as reported by other
researchers.44,45 With regard to the overall sensitivity, our
findings showed that Daoy cells were the most sensitive cell
line to the cytotoxic actions of 5-FU-loadedNPs, followed by
HepG2 and HT-29 cells.
Many chemotherapeutic agents, including 5-FU, are
shown to exert their anticancer effects through the induc-
tion of apoptosis. Numerous studies confirm that 5-FU
induces apoptosis in colon cancer cells, including HT-29
cells, as well as in extra-colonic cells.52 5-FU has been the
mainstay of CRC therapy since the late 1950;53 thus we
sought to determine the extent to which our 5-FU NP
formulas can induce apoptosis of the CRC HT-29 cell
line. The ability of our formulations F1–F3 to stimulate
early apoptosis in HT-29 human colon cancer is also con-
sistent with the cell anti-proliferative effects found in MTT
assay data, which illustrated that the three formulations
inhibited HT-29 cell viabilities within 48 hrs, compared to
control. (See MTT Figures). Our results corroborate pre-
vious reports showing that 5-FU NPs stimulate apoptosis
of colon cancer cells and that 5-FU NPs were superior to
free 5-FU.54,55
Conclusion
In this study, the physical incorporation of PEG 6000 in the
formulation 5-FU-loaded PLGA and PCL NPs has been suc-
cessfully achieved using a simple yet robust method with high
percent yield. The generated NPs exhibited relatively small
nanoparticle sizes, uniform spherical-shape, reasonable EE%,
andDL%. The in vitro release profiles of these NPs indicated a
Figure 7 Effect of several formulas of 5-FU-loaded nanoparticles on human colorectal cancer cells. HT-29 cells were treated with indicated formulas of 5-FU-loaded
nanoparticles (5-FU-Fx), unloaded nanoparticles (U-Fx), pure 5-FU or buffer (control) for 24, 48, or 72 hrs. Cell viability was determined by MTT assay as indicated in
Methods. At the end of the assay, the absorbance at 549 nm was read on a microplate reader. Significant differences between treatments and control and 5-FU were analyzed
by ANOVA followed by unpaired t-test. *p < 0.05 compared with control (0 µM). #P<0.05 compared with 5-FU.
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prolonged release which extended over 3 days. The in vitro
cytotoxicity studies indicated a highly significant activity of
5-FU when loaded into polymeric NPs than the pure drug.
Some of the formulations have demonstrated ability to stimu-
late apoptosis in HT-29 human colon cancer cells. Physical
PEGylation appeared to improve multiple characteristics of
NPs including the drug loading capacity and enhance both
drug release profile and in vitro cytotoxicity. Therefore, encap-
sulation of 5-FU into physically PEGylated PCL/PLGA NPs
can be considered a beneficial approach for enhancing the
efficacy of 5-FU and can be extended for many other drugs
to enhance their anticancer effects. The in vivo studies using
physically PEGylated PCL/PLGA NPs may yield additional
information on use of these NPs in cancer therapy.
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